


Listing of Claims

1. - 79. (Canceled)

80. (Previously Presented) A method of inhibiting an aberrant activity of a gastrin releasing peptide (GRP), comprising: contacting the peptide with an effective amount of a pharmaceutical composition comprising a compound of formula XV', wherein XV' is:



.


81. (Previously Presented) The method of claim 80, wherein the aberrant GRP activity is stimulating intracellular levels of one or both of IP₃ or Ca⁺².

82. -89. (Canceled)

90. (Previously Presented) A method of treating a condition by inhibiting an aberrant activity of GRP, comprising:

selecting a subject who is expressing GRP aberrantly or has an aberrant GRP activity and is in need of such treatment; and

administering to the subject an effective amount of a pharmaceutical composition comprising a compound of formula XV', wherein XV' is:



.

91. (Withdrawn) The method of claim 90, wherein the condition is hypotension, an eating disorder in which stimulation of food intake is desirable, or bronchopulmonary dysplasia.

92. (Withdrawn) The method of claim 90, wherein the condition is mediated by aberrant angiogenesis.

93. (Withdrawn) The method of claim 92, wherein the condition is selected from the group consisting of: arthritis, psoriasis, benign growths caused by rapidly dividing cells, brain ischaemia, atherosclerosis, myocardial angiogenesis, post-balloon angioplasty, vascular restenosis, neointima formation following vascular trauma, vascular graft restenosis, coronary collateral formation, deep venous thrombosis, ischemic limb angiogenesis, diabetic neovascularization, neovascular glaucoma, macular degeneration, diabetic and other retinopathy, retrobulbar fibroplasias, corneal diseases, fibrosis, deep venous thrombosis, endometriosis, and wrinkles.

94. (Withdrawn) The method of claim 92, wherein the condition is angiogenesis-mediated growth of a solid tumor.

95. (Withdrawn) The method of claim 94, wherein the tumor is a sarcoma, carcinoma, lymphoma, malignant melanoma, or benign tumor.

96. (Withdrawn) The method of claim 94, wherein the tumor growth comprises primary tumor growth, tumor invasion, metastasis, or two or more thereof.


97. (Withdrawn) The method of claim 94, wherein the tumor is a cancer selected from the group consisting of: adrenal, glioma, astrocytoma, neuroblastoma, renal, lung, pancreatic, gastric, gastrointestinal, colon, colorectal, prostate, ovarian, and breast.

98-99. (Canceled)

100. (Previously Presented) A method of inhibiting angiogenesis-mediated growth of a solid tumor in a subject in need of such treatment, comprising:

selecting a subject who is expressing GRP aberrantly or has an aberrant GRP activity, wherein the aberrant GRP expression or aberrant GRP activity is inducing angiogenesis; and

administering to the subject an effective amount of a pharmaceutical composition comprising a compound of formula XV', wherein XV' is:



101. (Previously Presented) The method of claim 100, wherein the tumor is a sarcoma, carcinoma, lymphoma, malignant melanoma, or benign tumor.

102. (Previously Presented) The method of claim 100, wherein the tumor growth comprises primary tumor growth, tumor invasion, metastasis, or two or more thereof.

103. (Previously Presented) The method of claim 100, wherein the tumor is a cancer selected from the group consisting of: adrenal, glioma, astrocytoma, neuroblastoma, renal, lung, pancreatic, gastric, gastrointestinal, colon, colorectal, prostate, ovarian, and breast.

104. (Previously Presented) The method of claim 80, wherein the peptide and the pharmaceutical composition are *in vitro*.

105. (Previously Presented) The method of claim 94, further comprising detecting or monitoring inhibition of angiogenesis.

106. (Previously Presented) The method of claim 94, further comprising detecting or monitoring reduction in tumor growth.

107. (Previously Presented) The method of claim 100, further comprising detecting or monitoring inhibition of angiogenesis.

108. (Previously Presented) The method of claim 100, further comprising detecting or monitoring reduction in tumor growth.